ACC/AHA/HFSA Release Updated Heart Failure Guidelines
The American College of Cardiology, American Heart Association, and the Heart Failure Society of America have issued part 2 of their guideline update on the management of heart failure. Part 1 of the update was released in May 2016.
The new recommendations update the 2013 ACCF/AHA Guideline for the Management of Heart Failure, and include revisions to the following sections: biomarkers, new therapies indicated for stage C heart failure with reduced ejection fraction, updates on heart failure with preserved ejection fraction, important comorbidities (including sleep apnea, anemia, and hypertension), and prevention of heart failure.
_________________________________________________________________________________________________________________________________
RELATED CONTENT
Diabetes Influences Outcomes in Chronic Heart Failure
Peripheral Artery Disease Influences Outcomes in Patients with Heart Failure
_________________________________________________________________________________________________________________________________
Among the recommendations:
- Measure natriuretic peptide biomarkers in patients presenting with dyspnea
- In chronic heart failure, B-type natriuretic peptide or N-terminal pro-B-type natriuretic peptide should be measured to determine prognosis or disease severity.
- Baseline levels of natriuretic peptide biomarkers and/or cardiac troponin is useful to establish prognosis.
- ACE inhibitors is beneficial in patients with heart failure with reduced ejection fraction.
- Systolic and diastolic blood pressure should be controlled in patients with heart failure with preserved ejection fraction.
—Michael Potts
Reference:
Bozkurt B, Butler J, Casey DE, et al. 2017ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure [published online May 1, 2017]. Circulation. DOI:10.1161/CIR.0000000000000509.